Kristin Yarema, Ph.D.’s Post

Webinar now available on-demand! Accelerating your gene therapy to patients: not all platforms are created equal In this webinar, George Buchman (Vice President, Pre-Clinical and Process Development, Catalent Cell & Gene Therapy) and Thomas VanCott (Chief Scientific Officer, Combined Therapeutics) explore how a complete platform approach to fast-track AAV vectors to the clinic can enhance quality and efficiency. They will also discuss how this method can provide a well-suited process for late-stage clinical GMP production. Watch to learn more about: • How standardized processes impact #AAV vector manufacturing efficiency, timelines and development, to use in the clinic • How clonal #HEK-293 suspension-based processes improve the scalability and yield of AAV vector production • The advantages off-the-shelf plasmids offer compared to commercial plasmid vectors in terms of yield and packaging efficiency when used with a platform clonal cell line Watch the #webinar at your convenience here:

When you've designed millions of square feet of research space for companies developing vaccine therapies, cell and gene therapies, and CRISPR/Cas9 therapeutics, as well as companies needing basic but also highly specialized BSL-3, cGMP and barrier facilities for immunocompromised and ABSL-2 animals, you say, YES This Is #ArchitctureofDiscovery. #Bostondesign #lifesciences #labplanner #labprogram #tourtuesday

💫 What a busy start today in London! 🇬🇧 There's still time to meet this afternoon, and if you don't catch us today, there's also an opportunity tomorrow. 👉🏼 We're ready for another productive day at booth #111! 💡 Discuss together how ReiThera’s capabilities can advance your gene therapy program or viral vaccine from preclinical to clinical and commercial production. #gmp #biotech #biotechnology #genetherapy #cellandgenetherapy #advancedtherapies #adtherapies24

Attended a webinar on The State of Cell and Gene Therapy today - it was a truly informative and insightful experience! Having recently completed a module on Biologics and Advanced Therapies led by none other than Prof. Bams Abila, MD, PhD, FFPM, the information presented made even more sense. Attending webinars like this provides a plethora of knowledge and helps in the holistic development of one's career. #lifelonglearning #professionaldevelopment

Exciting collaboration with GenSight Biologics! Be sure to join Scott Jeffers Ph.D. (Chief Technology Officer) from GenSight Biologics at ASGCT #ASGCT2024 May 9 at 12pm. Details below: Poster 1031 Increased Reproducibility in a Critical Downstream Processing Step allows for Speed to Commercialization of Gene Therapy Product to Treat Leber’s Hereditary Optic Neuropathy (LHON) #verdot I #gensightbiologics I #ASGCT2024 I #innovation I #bioprocessing I #singleuse I #purification

Yesterday got off to a busy start here at the #ESGCT23, and we're ready for another productive day.   💡 Want to learn how ReiThera’s capabilities can advance your gene therapy program or viral vaccine from preclinical to clinical and commercial production? Come and meet us at booth #45 and speak with our specialists.   #gmp #biotech #biotechnology #genetherapy #cellandgenetherapy #esgct23

An interesting discussion regarding #FDA approvals for #sicklecelldisease, Vertex Pharmaceuticals, bluebird bio, #Vandapharmacueticals and the #EUAiAct #vertex #bluebirdbio #pharma #ai #genai

Don't miss the new Drug Discovery World newsletter, with all the latest in cancer research and gene therapy news, as well as analysis of the RNA landscape and AI's role in drug repurposing. https://lnkd.in/e3Q6ZNUa #drugdiscovery #drugdevelopment #pharma #biotech #newsletter

Watch our on-demand webinar on overcoming upstream and downstream process barriers for large-scale AAV production! Watch our esteemed speakers from Encoded Therapeutics and Thermo Fisher Scientific share their valuable insights and strategies to optimize your AAV manufacturing process, ultimately accelerating the development of safe and effective gene therapies. Key Takeaways: ✅ Discover an end-to-end solution for the development and commercial production of AAV. ✅ Learn about new products and technologies that can enhance production efficiency, address regulatory concerns, and facilitate the scale-up of AAV production protocols. ✅ Gain a comprehensive understanding of how gene therapy developers are currently tackling critical manufacturing challenges.

ASGCT #ASGCT2024 is less than a week away! Check out our collaboration 🤝 with GenSight Biologics: Scott Jeffers Ph.D. (Chief Technology Officer) will be presenting a poster on May 9 at 12PM EST. Details below 👇 🔦 Poster 1031 Increased Reproducibility in a Critical Downstream Processing Step allows for Speed to Commercialization of Gene Therapy Product to Treat Leber’s Hereditary Optic Neuropathy (LHON) #verdot I #gensightbiologics I #ASGCT2024 I #innovation I #bioprocessing I #singleuse I #purification